title: Photodynamic dose does not correlate with long-term tumor response to mTHPC-PDT performed at several drug-light intervals.
abstract: Meso-tetra-hydroxyphenyl-chlorin (mTHPC, Foscan), a promising photosensitizer for photodynamic therapy (PDT), is approved in Europe for the palliative treatment of head and neck cancer. Based on work in mice that investigated optimal tumor accumulation, clinical protocols with Foscan typically employ an interval of 96 h between systemic sensitizer administration and irradiation. However, recent studies in mouse tumor models have demonstrated significantly improved long-term tumor response when irradiation is performed at shorter drug-light intervals of 3 and 6 h. Using a previously published theoretical model of microscopic PDT dosimetry and informed by experimentally determined photophysical properties and intratumor sensitizer concentrations and distributions, we calculated photodynamic dose depositions following mTHPC-PDT for drug-light intervals of 3, 6, 24, and 96 h. Our results demonstrate that the singlet oxygen dose to the tumor volume does not track even qualitatively with tumor responses for these four drug-light intervals. Further, microscopic analysis of simulated singlet oxygen deposition shows that in no case do any subpopulations of tumor cells receive a threshold dose. Indeed, under the conditions of these simulations more than 90% of the tumor volume receives a dose that is approximately 20-fold lower than the threshold dose for mTHPC. Thus, in this evaluation of mTHPC-PDT at various drug-light intervals, any PDT dose metric that is proportional to singlet oxygen creation and/or deposition would fail to predict the tumor response. In situations like this one, other reporters of biological response to therapy would be necessary.
authors.affiliation: Department of Physics and Astronomy, University of Rochester, Rochester, New York 14627, USA.
authors.forename: Ken Kang-Hsin
authors.initials: KK
authors.lastname: Wang
authors.forename: Soumya
authors.initials: S
authors.lastname: Mitra
authors.forename: Thomas H
authors.initials: TH
authors.lastname: Foster
mesh_terms: D000465:Algorithms; D000818:Animals; D003198:Computer Simulation; D004195:Disease Models, Animal; D008652:Mesoporphyrins / Q000627:therapeutic use*; D051379:Mice; D008954:Models, Biological; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D010778:Photochemotherapy / Q000379:methods*; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011829:Radiation Dosage; D026082:Singlet Oxygen / Q000378:metabolism; D013997:Time Factors
chemical_list: D008652:Mesoporphyrins; D017319:Photosensitizing Agents; D026082:Singlet Oxygen; C072269:temoporfin
references.citation: Photochem Photobiol. 2005 Jan-Feb;81(1):196-205
references.pmid: 15469385
references.citation: J Photochem Photobiol B. 2005 Jun 1;79(3):231-41
references.pmid: 15896650
references.citation: Neoplasia. 2008 May;10(5):429-38
references.pmid: 18472960
references.citation: Br J Cancer. 1997;76(8):1021-8
references.pmid: 9376261
references.citation: Proc R Soc Lond B Biol Sci. 1964 Dec 15;161:247-74
references.pmid: 14224411
references.citation: Cell Death Differ. 2002 Sep;9(9):934-44
references.pmid: 12181744
references.citation: Photochem Photobiol. 2005 Jul-Aug;81(4):849-59
references.pmid: 15807635
references.citation: Br J Cancer. 2003 Jan 27;88(2):283-90
references.pmid: 12610515
references.citation: Radiat Res. 2003 Oct;160(4):452-9
references.pmid: 12968929
references.citation: Photochem Photobiol. 1997 Jan;65(1):135-44
references.pmid: 9066293
references.citation: Photochem Photobiol. 2005 Sep-Oct;81(5):1123-30
references.pmid: 15971933
references.citation: Photochem Photobiol. 2003 Dec;78(6):615-22
references.pmid: 14743872
references.citation: Lasers Surg Med. 2006 Jun;38(5):509-15
references.pmid: 16788921
references.citation: Radiat Res. 1998 Nov;150(5 Suppl):S146-56
references.pmid: 9806617
references.citation: Head Neck. 2004 Mar;26(3):232-40
references.pmid: 14999798
references.citation: Clin Cancer Res. 2005 May 1;11(9):3543-52
references.pmid: 15867258
references.citation: Photochem Photobiol. 2002 Mar;75(3):289-95
references.pmid: 11950095
references.citation: Cancer Res. 1996 Jul 1;56(13):2908-11
references.pmid: 8674038
references.citation: Cancer Res. 1985 Feb;45(2):572-6
references.pmid: 3967232
references.citation: Photochem Photobiol. 2006 Sep-Oct;82(5):1198-210
references.pmid: 16808593
references.citation: Photochem Photobiol. 2005 Sep-Oct;81(5):1161-7
references.pmid: 15934792
references.citation: Cancer Res. 2000 Mar 15;60(6):1637-44
references.pmid: 10749134
references.citation: Photochem Photobiol. 1998 Sep;68(3):281-8
references.pmid: 9747583
references.citation: Photochem Photobiol Sci. 2002 Sep;1(9):690-5
references.pmid: 12665307
references.citation: Nat Med. 2003 Oct;9(10):1327-31
references.pmid: 14502284
references.citation: Photochem Photobiol. 2002 Mar;75(3):282-8
references.pmid: 11950094
references.citation: Photochem Photobiol. 2001 Mar;73(3):297-303
references.pmid: 11281027
references.citation: Lancet Oncol. 2004 Aug;5(8):497-508
references.pmid: 15288239
references.citation: Photochem Photobiol. 1999 Jan;69(1):61-70
references.pmid: 10063801
references.citation: Opt Lett. 2003 May 1;28(9):695-7
references.pmid: 12747710
references.citation: Med Phys. 2004 Jul;31(7):1949-59
references.pmid: 15305445
references.citation: Med Phys. 2007 Jan;34(1):282-93
references.pmid: 17278514
references.citation: J Biomed Opt. 2001 Oct;6(4):457-67
references.pmid: 11728206
references.citation: Br J Cancer. 2003 Jul 21;89(2):398-404
references.pmid: 12865935